EMERYVILLE, Calif., Sept. 13 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI, BNVID), a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that Dr. Isaac Cohen, O.M.D, Chairman and Chief Executive Officer and Mr. Tom Chesterman, Chief Financial Officer, will be presenting at a Cambria Capital investor meeting at 4:00 p.m. MST on Thursday, September 16, 2010. The event will be held at Yorgio's Restaurant in Salt Lake City, UT.
Interested parties can contact Joel Vanderhoof at 801-320-9609 or Jason Carter at 801-320-9608, both of Cambria Capital to reserve a spot. A copy of the presentation will also be available at http://bionovo.com/investors/events.
About Cambria Capital, LLC
Cambria Capital, LLC ("Cambria") is an investment banking and securities brokerage firm with offices in Salt Lake City, Los Angeles and San Francisco. Cambria's mission is to facilitate the growth and development of promising companies at all stages of development by providing capital and a wide variety of financial advisory services. The financing arranged by Cambria originates from a number of sources, including the firm's principals and Cambria's network of high net-worth individuals and institutional investors. Cambria employs a number of corporate finance structures, including PIPEs (Private Investments in Public Equities), private placements of equity and debt securities and reverse mergers. Cambria is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit the Cambria website at http://www.cambriacapital.com.
About Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the Nasdaq Capital Market under the symbol, "BNVI, BNVID". For more information about Bionovo and its programs, visit http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
|SOURCE Bionovo, Inc.|
Copyright©2010 PR Newswire.
All rights reserved